Achieve Life Sciences, Inc. (ACHV)
Achieve Life Sciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Bothell, WA, US. The stock last traded at $8.39, up 5.67% on the session, giving a market capitalisation of $861.3M. On trailing twelve-month figures it carries a trailing P/E of -5.41, a net margin of 0.0%. Its beta of 2.23 implies it has historically moved more than the broad market.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Achieve Life Sciences, Inc. is most often compared with the following Healthcare names: